Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $86.5 in the prior trading day, Globus Medical Inc (NYSE: GMED) closed at $85.79, down -0.82%. In other words, the price has decreased by -$0.82 from its previous closing price. On the day, 1.32 million shares were traded. GMED stock price reached its highest trading level at $87.34 during the session, while it also had its lowest trading level at $85.26.
Ratios:
Our goal is to gain a better understanding of GMED by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 29.57 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.92. For the most recent quarter (mrq), Quick Ratio is recorded 2.47 and its Current Ratio is at 4.13. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
On November 07, 2025, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $91.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 12 ’25 when Norwalk Leslie V sold 4,000 shares for $88.85 per share. The transaction valued at 355,400 led to the insider holds 12,419 shares of the business.
Norwalk Leslie V bought 4,000 shares of GMED for $355,000 on Dec 12 ’25. On Dec 01 ’25, another insider, Kline Kyle, who serves as the Senior Vice President, CFO of the company, sold 18,542 shares for $90.00 each. As a result, the insider received 1,668,780 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMED now has a Market Capitalization of 11586561024 and an Enterprise Value of 11211653120. As of this moment, Globus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 27.73, and their Forward P/E ratio for the next fiscal year is 21.28. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.76. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.17 while its Price-to-Book (P/B) ratio in mrq is 2.63. Its current Enterprise Value per Revenue stands at 4.048 whereas that against EBITDA is 14.021.
Stock Price History:
The Beta on a monthly basis for GMED is 1.07, which has changed by 0.057715774 over the last 52 weeks, in comparison to a change of 0.16081822 over the same period for the S&P500. Over the past 52 weeks, GMED has reached a high of $94.93, while it has fallen to a 52-week low of $51.79. The 50-Day Moving Average of the stock is 14.61%, while the 200-Day Moving Average is calculated to be 30.44%.
Shares Statistics:
The stock has traded on average 1.75M shares per day over the past 3-months and 1529790 shares per day over the last 10 days, according to various share statistics. A total of 112.18M shares are outstanding, with a floating share count of 111.35M. Insiders hold about 17.28% of the company’s shares, while institutions hold 88.30% stake in the company. Shares short for GMED as of 1764288000 were 4397222 with a Short Ratio of 2.52, compared to 1761868800 on 7150376. Therefore, it implies a Short% of Shares Outstanding of 4397222 and a Short% of Float of 4.4299997.
Earnings Estimates
As of right now, 12.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.89, with high estimates of $0.98 and low estimates of $0.79.
Analysts are recommending an EPS of between $3.81 and $3.76 for the fiscal current year, implying an average EPS of $3.79. EPS for the following year is $4.11, with 12.0 analysts recommending between $4.3 and $3.85.
Revenue Estimates
11 analysts predict $777.51M in revenue for. The current quarter. It ranges from a high estimate of $788.6M to a low estimate of $767.5M. As of. The current estimate, Globus Medical Inc’s year-ago sales were $657.29MFor the next quarter, 11 analysts are estimating revenue of $726.05M. There is a high estimate of $749.8M for the next quarter, whereas the lowest estimate is $698.93M.
A total of 12 analysts have provided revenue estimates for GMED’s current fiscal year. The highest revenue estimate was $2.9B, while the lowest revenue estimate was $2.88B, resulting in an average revenue estimate of $2.89B. In the same quarter a year ago, actual revenue was $2.52BBased on 12 analysts’ estimates, the company’s revenue will be $3.12B in the next fiscal year. The high estimate is $3.16B and the low estimate is $3.06B.
